http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 19 Oct 2026 08:01:05 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NCI+awards+%242.9M+to+study+RedHill+drug+with+CAR+T-cell+therapy/27200972.html <p>The University of Oklahoma has received a five-year, $2.9 million grant from the National Cancer Institute to study whether RedHill Biopharma's (NASDAQ: RDHL) investigational drug opaganib, used after CAR T-cell therapy, may help immune cells fight multiple myeloma more effectively.</p> <p>The grant will fund two phases of clinical trials. A Phase 1b trial plans to enroll up to 18 patients to evaluate the safety of combining CAR T-cell therapy with opaganib and to determine appropriate dosing. A subsequent Phase 2 trial plans to enroll up to 21 additional patients to seek preliminary evidence of effectiveness.</p> <p>CAR T-cell therapy genetically modifies a patient's http://www.streetinsider.com/Corporate+News/NCI+awards+%242.9M+to+study+RedHill+drug+with+CAR+T-cell+therapy/27200972.html Mon, 19 Oct 2026 08:01:05 -0400 RDHL http://www.streetinsider.com/FDA/NCI+awards+%242.9M+to+study+RedHill+drug+with+CAR+T-cell+therapy/27200972.html <p>The University of Oklahoma has received a five-year, $2.9 million grant from the National Cancer Institute to study whether RedHill Biopharma's (NASDAQ: RDHL) investigational drug opaganib, used after CAR T-cell therapy, may help immune cells fight multiple myeloma more effectively.</p> <p>The grant will fund two phases of clinical trials. A Phase 1b trial plans to enroll up to 18 patients to evaluate the safety of combining CAR T-cell therapy with opaganib and to determine appropriate dosing. A subsequent Phase 2 trial plans to enroll up to 21 additional patients to seek preliminary evidence of effectiveness.</p> <p>CAR T-cell therapy genetically modifies a patient's http://www.streetinsider.com/FDA/NCI+awards+%242.9M+to+study+RedHill+drug+with+CAR+T-cell+therapy/27200972.html Mon, 19 Oct 2026 08:01:05 -0400 RDHL http://www.streetinsider.com/Press+Releases/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and RALEIGH, N.C.</span>, <span class="legendSpanClass"><chron>Oct. 19, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1481362928" idsrc="xmltag.org" >RedHill Biopharma Ltd.</span> (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the <span value="ACORN:0684345211" idsrc="xmltag.org" >University of Oklahoma</span> (OU), has received <money>$2.9 million</money> in funding from the <span value="ACORN:6000176586" idsrc="xmltag.org" >National Cancer Institute</span> (NCI) to study, in clinical trials, whether RedHill's opaganib[1], given after CAR (chimeric antigen receptor) T-cell therapy, may help immune cells fight cancer more effectively.</p> http://www.streetinsider.com/Press+Releases/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html Mon, 19 Oct 2026 08:00:00 -0400 RDHL RDHL http://www.streetinsider.com/PRNewswire/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and RALEIGH, N.C.</span>, <span class="legendSpanClass"><chron>Oct. 19, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1481362928" idsrc="xmltag.org" >RedHill Biopharma Ltd.</span> (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the <span value="ACORN:0684345211" idsrc="xmltag.org" >University of Oklahoma</span> (OU), has received <money>$2.9 million</money> in funding from the <span value="ACORN:6000176586" idsrc="xmltag.org" >National Cancer Institute</span> (NCI) to study, in clinical trials, whether RedHill's opaganib[1], given after CAR (chimeric antigen receptor) T-cell therapy, may help immune cells fight cancer more effectively.</p> http://www.streetinsider.com/PRNewswire/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html Mon, 19 Oct 2026 08:00:00 -0400 RDHL RDHL http://www.streetinsider.com/Press+Releases/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and RALEIGH, N.C.</span>, <span class="legendSpanClass"><chron>Oct. 19, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1481362928" idsrc="xmltag.org" >RedHill Biopharma Ltd.</span> (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the <span value="ACORN:0684345211" idsrc="xmltag.org" >University of Oklahoma</span> (OU), has received <money>$2.9 million</money> in funding from the <span value="ACORN:6000176586" idsrc="xmltag.org" >National Cancer Institute</span> (NCI) to study, in clinical trials, whether RedHill's opaganib[1], given after CAR (chimeric antigen receptor) T-cell therapy, may help immune cells fight cancer more effectively.</p> http://www.streetinsider.com/Press+Releases/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html Mon, 19 Oct 2026 08:00:00 -0400 RDHL RDHL http://www.streetinsider.com/PRNewswire/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and RALEIGH, N.C.</span>, <span class="legendSpanClass"><chron>Oct. 19, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1481362928" idsrc="xmltag.org" >RedHill Biopharma Ltd.</span> (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the <span value="ACORN:0684345211" idsrc="xmltag.org" >University of Oklahoma</span> (OU), has received <money>$2.9 million</money> in funding from the <span value="ACORN:6000176586" idsrc="xmltag.org" >National Cancer Institute</span> (NCI) to study, in clinical trials, whether RedHill's opaganib[1], given after CAR (chimeric antigen receptor) T-cell therapy, may help immune cells fight cancer more effectively.</p> http://www.streetinsider.com/PRNewswire/%242.9+Million+NCI+Grant+Awarded+for+Clinical+Development+of+RedHill%27s+Opaganib+and+CAR+T-Cell+Combination+in+Ultra-High-Risk+Multiple+Myeloma/27200953.html Mon, 19 Oct 2026 08:00:00 -0400 RDHL RDHL http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Press+Releases/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html <p>SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- <em>USA Newsroom</em> News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the S&amp;P 500, the Nasdaq Composite and the Russell 2000 were all lower for the week, with small caps taking the hardest hit as the 10-year Treasury yield climbed 6 basis points on the week to 5.24%, according to the latest edition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oHW3y8M4JvOTICS1_SYw1YmoCjspeyshn1tMGhDvaA1-tplQaJQtpqST1tdGnfAzRa6NYnjCpB7O26nrMBRqdZybq-piuiYVeKXOgsM8V420hTZbhPftdXuO37Hi4ITHWRqaxG-usGMJsNtjEWaZX-LJ69pYTYJjnrUL-WS3_SN5GewJ0eHBU9ll6ffcaqGvrT7x3dcyUzqg9nZfsLlYmw==" rel="nofollow" target="_blank">The Roadmap from Stock Preachers</a>. At the same time, a fresh batch of company results http://www.streetinsider.com/Globe+Newswire/Small+Caps+Test+Their+200-Day+Line+as+Yields+Grind+Higher+and+Earnings+Season+Stirs/27137517.html Thu, 01 Oct 2026 18:24:00 -0400 CAG MKC RCON RDHL WTW http://www.streetinsider.com/Press+Releases/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html <div class="xn-content"> <p class="prntac"><i>Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota^® and Clenpiq^®, two established <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>-approved gastrointestinal (GI) brands that generated <money>$37.5 million</money> in 2025 net sales under <span value="ACORN:2651335501" idsrc="xmltag.org" >Ferring Pharmaceuticals</span> ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion</i></p> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/us.nc.raleig" idsrc="xmltag.org" >RALEIGH, N.C.</location></span>, http://www.streetinsider.com/Press+Releases/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html Wed, 30 Sep 2026 16:05:00 -0400 RDHL RDHL http://www.streetinsider.com/PRNewswire/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html <div class="xn-content"> <p class="prntac"><i>Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota^® and Clenpiq^®, two established <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>-approved gastrointestinal (GI) brands that generated <money>$37.5 million</money> in 2025 net sales under <span value="ACORN:2651335501" idsrc="xmltag.org" >Ferring Pharmaceuticals</span> ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion</i></p> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/us.nc.raleig" idsrc="xmltag.org" >RALEIGH, N.C.</location></span>, http://www.streetinsider.com/PRNewswire/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html Wed, 30 Sep 2026 16:05:00 -0400 RDHL RDHL http://www.streetinsider.com/Press+Releases/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html <div class="xn-content"> <p class="prntac"><i>Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota^® and Clenpiq^®, two established <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>-approved gastrointestinal (GI) brands that generated <money>$37.5 million</money> in 2025 net sales under <span value="ACORN:2651335501" idsrc="xmltag.org" >Ferring Pharmaceuticals</span> ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion</i></p> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/us.nc.raleig" idsrc="xmltag.org" >RALEIGH, N.C.</location></span>, http://www.streetinsider.com/Press+Releases/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html Wed, 30 Sep 2026 16:05:00 -0400 RDHL RDHL http://www.streetinsider.com/PRNewswire/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html <div class="xn-content"> <p class="prntac"><i>Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota^® and Clenpiq^®, two established <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>-approved gastrointestinal (GI) brands that generated <money>$37.5 million</money> in 2025 net sales under <span value="ACORN:2651335501" idsrc="xmltag.org" >Ferring Pharmaceuticals</span> ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion</i></p> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/us.nc.raleig" idsrc="xmltag.org" >RALEIGH, N.C.</location></span>, http://www.streetinsider.com/PRNewswire/RedHill+Biopharma+Announces+Operational+Highlights+and+First+Half+2026+Financial+Results/27128651.html Wed, 30 Sep 2026 16:05:00 -0400 RDHL RDHL http://www.streetinsider.com/Mergers+and+Acquisitions/RedHill+acquires+Ferring%27s+Rebyota+and+Clenpiq+for+%2412M+upfront/27008634.html <p>RedHill Biopharma Ltd. (NASDAQ: RDHL) announced it has acquired exclusive commercialization rights to two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq, from Ferring Pharmaceuticals, according to a company statement dated September 1, 2026.</p> <p>Under the terms of the agreement, RedHill paid $12 million upfront to Ferring, plus tiered royalties on net sales and potential future milestones. The upfront payment was funded through RedHill's previously announced $18 million divestiture of its Talicia product. RedHill received exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq.</p> <p>The two products together generated approximately $37.5 million in 2025 U.S. net sales. Rebyota, a single-dose http://www.streetinsider.com/Mergers+and+Acquisitions/RedHill+acquires+Ferring%27s+Rebyota+and+Clenpiq+for+%2412M+upfront/27008634.html Tue, 01 Sep 2026 07:00:25 -0400 RDHL http://www.streetinsider.com/Press+Releases/RedHill+Announces+Transformational+Acquisition+of+Commercialization+Rights+to+Ferring%E2%80%99s+Rebyota%C2%AE+and+Clenpiq%C2%AE/27008578.html <p align="center" style="padding-left:0pt;"><img alt="Redhill Biopharma Ltd." src="https://ml.globenewswire.com/Resource/Download/b4f73c57-9f49-4c60-8d50-4abafd908297/image1.jpg" data-dpi="96" data-caption="Redhill Biopharma Ltd." data-filename="image1.jpg" /><br /></p> <p style="padding-left:0pt;">Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill’s commercial GI business</p> <p style="padding-left:0pt;">The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional http://www.streetinsider.com/Press+Releases/RedHill+Announces+Transformational+Acquisition+of+Commercialization+Rights+to+Ferring%E2%80%99s+Rebyota%C2%AE+and+Clenpiq%C2%AE/27008578.html Tue, 01 Sep 2026 07:00:00 -0400 RDHL http://www.streetinsider.com/Globe+Newswire/RedHill+Announces+Transformational+Acquisition+of+Commercialization+Rights+to+Ferring%E2%80%99s+Rebyota%C2%AE+and+Clenpiq%C2%AE/27008578.html <p align="center" style="padding-left:0pt;"><img alt="Redhill Biopharma Ltd." src="https://ml.globenewswire.com/Resource/Download/b4f73c57-9f49-4c60-8d50-4abafd908297/image1.jpg" data-dpi="96" data-caption="Redhill Biopharma Ltd." data-filename="image1.jpg" /><br /></p> <p style="padding-left:0pt;">Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill’s commercial GI business</p> <p style="padding-left:0pt;">The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional http://www.streetinsider.com/Globe+Newswire/RedHill+Announces+Transformational+Acquisition+of+Commercialization+Rights+to+Ferring%E2%80%99s+Rebyota%C2%AE+and+Clenpiq%C2%AE/27008578.html Tue, 01 Sep 2026 07:00:00 -0400 RDHL http://www.streetinsider.com/Corporate+News/RedHill+sells+Talicia+to+Apotex+for+%2418M+upfront+plus+milestones/27000835.html <p>RedHill Biopharma Ltd. (NASDAQ: RDHL) has divested its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for an upfront cash payment of $18 million, plus up to $35 million in additional payments tied to worldwide net sales milestones, according to a company statement.</p><p>Under the agreement, Apotex acquires RedHill's 70% interest in Talicia, an H. pylori treatment. The transaction follows Apotex's prior acquisition of Cumberland Pharmaceuticals Inc.'s U.S. branded business, which included Cumberland's 30% ownership stake in Talicia, giving Apotex full ownership of the product.</p><p>RedHill Chief Executive Officer Dror Ben-Asher said the deal converts the company's stake in http://www.streetinsider.com/Corporate+News/RedHill+sells+Talicia+to+Apotex+for+%2418M+upfront+plus+milestones/27000835.html Mon, 31 Aug 2026 07:01:09 -0400 APTX. RDHL http://www.streetinsider.com/Corporate+News/RedHill+sells+Talicia+to+Apotex+for+%2418M+upfront+plus+milestones/27000835.html <p>RedHill Biopharma Ltd. (NASDAQ: RDHL) has divested its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for an upfront cash payment of $18 million, plus up to $35 million in additional payments tied to worldwide net sales milestones, according to a company statement.</p><p>Under the agreement, Apotex acquires RedHill's 70% interest in Talicia, an H. pylori treatment. The transaction follows Apotex's prior acquisition of Cumberland Pharmaceuticals Inc.'s U.S. branded business, which included Cumberland's 30% ownership stake in Talicia, giving Apotex full ownership of the product.</p><p>RedHill Chief Executive Officer Dror Ben-Asher said the deal converts the company's stake in http://www.streetinsider.com/Corporate+News/RedHill+sells+Talicia+to+Apotex+for+%2418M+upfront+plus+milestones/27000835.html Mon, 31 Aug 2026 07:01:09 -0400 APTX. RDHL